Research Investments

How we fund innovative colorectal cancer research

Our research program is a critical driving force in our mission to end colorectal cancer in our lifetime. We've invested nearly $5 million in colorectal cancer research, including nearly $3 million as early-stage grants to innovative researchers. Learn more about how our funding mechanisms guide our investments in colorectal cancer research.

How we fund research

Explore our colorectal cancer research areas

Click on a research focus to see how we're using our research funds to accelerate treatment, prevention, and a cure.

Young-onset colorectal cancer

Colorectal cancer is rising in people under 50, and no one knows why. We invest in research that aims to understand more about colorectal cancer in young people and how to prevent it.

Health disparities

Colorectal cancer rates vary among racial groups, age, and socioeconomic status. We support research that helps us understand why and how to improve early detection and treatment among diverse populations.

Rectal cancer

Nearly 50,000 people with be diagnosed with rectal cancer this year. We awards grants to encourage research in rectal cancer and to establish a successful career path in this field.

Prevention

Colorectal cancer is one of the few cancers that is preventable. We support researchers studying what motivates people to get screened earlier and detect or prevent this unique cancer.

Treatments

More survivors are beating colorectal cancer than ever before. However, we still have a long way to go. We need breakthroughs for advanced colorectal cancer and less toxic and more effective cancer treatments.

Early investigator grants

There is a tremendous unmet need for advancements in screening, treating, and caring for people with colorectal cancer. To foster innovation, we support the training of colorectal cancer researchers.

In-house colorectal cancer research

We put patients at the center of everything we do. Through in-house research, we are building knowledge around critical issues for patients’ direct benefit.

Young-onset CRC research

Our Never Too Young patient and caregiver reports highlight the experiences and needs of the young-onset colorectal cancer community.

Biomarker research

We are committed to understanding patient and caregiver barriers to accessing the benefits of biomarker testing, while developing the resources and navigation to assist them.